CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $243.79M, lower than 95% of all stocks globally
- PositionOperating margin is -36426.9%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
38.91BJPY243.79M · vs all stocks (USD)
Trailing P/E
243.88xvs Biotechnology peers
Revenue (TTM)
3.03BJPY18.96M · vs all stocks (USD)
Profit Margin
19.58%vs Biotechnology peers
Beta
-0.8540xvs all stocks
52-Week Change
-42.32%vs all stocks
Market Capitalization
38.91BJPY243.79M · vs all stocks (USD)
Enterprise Value
40.87BJPY256.08M · vs all stocks (USD)
Trailing P/E
243.88xvs Biotechnology peers
Forward P/E
-18.41xvs Biotechnology peers
Price to Sales (TTM)
15.21xvs Biotechnology peers
Price to Book (MRQ)
6.44xvs Biotechnology peers
Enterprise to Revenue
13.50xvs Biotechnology peers
Enterprise to EBITDA
53.20xvs Biotechnology peers
Profit Margin
19.58%vs Biotechnology peers
Return on Assets (TTM)
5.97%vs Biotechnology peers
Return on Equity (TTM)
8.35%vs Biotechnology peers
Revenue (TTM)
3.03BJPY18.96M · vs all stocks (USD)
Revenue per Share (TTM)
134.24JPYUpdated Aug 19, 2026Gross Profit (TTM)
3.03BJPY18.96M · vs all stocks (USD)
EBITDA (TTM)
342.15MJPY2.14M · vs all stocks (USD)
Net Income (TTM)
592.50MJPY3.71M · vs all stocks (USD)
Operating Cash Flow (TTM)
1.08BJPY6.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
190.61MJPY1.19M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00JPYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.03BJPYFY2025 · Oct 31, 2025Cost of Goods Sold
0.00JPYFY2025 · Oct 31, 2025Gross Profit
3.03BJPYFY2025 · Oct 31, 2025Operating Income
272.16MJPY1.71M · vs all stocks (USD)
Pre-tax Income
288.99MJPYFY2025 · Oct 31, 2025Income Tax Expense
98.38MJPYFY2025 · Oct 31, 2025Net Income
190.61MJPYFY2025 · Oct 31, 2025EBIT
289.14MJPYFY2025 · Oct 31, 2025EBITDA (Income Statement)
342.15MJPYFY2025 · Oct 31, 2025Non-operating Interest Income
5.92MJPYFY2025 · Oct 31, 2025Non-operating Interest Expense
159.00KJPYFY2025 · Oct 31, 2025Preferred Stock Dividends
0.00JPYFY2025 · Oct 31, 2025Operating Cash Flow
973.13MJPYFY2025 · Oct 31, 2025Free Cash Flow
944.45MJPYFY2025 · Oct 31, 2025Cash & Cash Equivalents (End of Period)
6.84BJPYFY2025 · Oct 31, 2025Starting Profit (CF Statement)
288.99MJPYFY2025 · Oct 31, 2025Other Non-cash Items
-97.28MJPYFY2025 · Oct 31, 2025Change in Accounts Receivable (CF)
749.46MJPYFY2025 · Oct 31, 2025Change in Other Assets/Liabilities
31.97MJPYFY2025 · Oct 31, 2025Capital Expenditures
-28.69MJPYFY2025 · Oct 31, 2025Other Investing Activity
101.32MJPYFY2025 · Oct 31, 2025Net Investing Cash Flow
72.64MJPYFY2025 · Oct 31, 2025Other Financing Charges
-1.00KJPYFY2025 · Oct 31, 2025Net Financing Cash Flow
381.05MJPYFY2025 · Oct 31, 2025Shares Outstanding
22.87MSharesUpdated Aug 19, 2026Float Shares
12.50MSharesUpdated Aug 19, 2026% Held by Insiders
46.50%vs all stocks
% Held by Institutions
2.31%vs all stocks
Total Cash (MRQ)
6.34BJPY39.69M · vs all stocks (USD)
Total Cash per Share (MRQ)
276.74JPYUpdated Aug 19, 2026Total Debt (MRQ)
252.00KJPY1.58K · vs all stocks (USD)
Current Ratio (MRQ)
18.48xvs Biotechnology peers
Book Value per Share (MRQ)
312.45JPYUpdated Aug 19, 2026Total Assets
7.68BJPY48.09M · vs all stocks (USD)
Total Current Assets
7.14BJPYFY2025 · Oct 31, 2025Total Liabilities
480.84MJPYFY2025 · Oct 31, 2025Total Non-current Assets
532.21MJPYFY2025 · Oct 31, 2025Total Non-current Liabilities
160.51MJPYFY2025 · Oct 31, 2025Total Current Liabilities
320.33MJPYFY2025 · Oct 31, 2025Cash & Cash Equivalents
6.84BJPYFY2025 · Oct 31, 2025Accounts Receivable
0.00JPYFY2025 · Oct 31, 2025Inventory
47.87MJPYFY2025 · Oct 31, 2025Short-term Debt
252.00KJPYFY2025 · Oct 31, 2025Other Current Liabilities
8.60MJPYFY2025 · Oct 31, 2025Long-term Debt
0.00JPYFY2025 · Oct 31, 2025Other Non-current Liabilities
2.00KJPYFY2025 · Oct 31, 2025Common Stock (Book)
1.33BJPYFY2025 · Oct 31, 2025Retained Earnings
-2.58BJPYFY2025 · Oct 31, 2025Total Shareholders' Equity
7.19BJPY45.08M · vs all stocks (USD)
52-Week Low
1.34KJPYUpdated Aug 19, 202652-Week High
3.85KJPYUpdated Aug 19, 202652-Week Change
-42.32%vs all stocks
Beta
-0.8540xvs all stocks
50-Day MA
1.67KJPYUpdated Aug 19, 2026200-Day MA
1.79KJPYUpdated Aug 19, 2026Avg 10-Day Volume
260.18KSharesUpdated Aug 19, 2026Avg 30-Day Volume
215.87KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
8.25JPYUpdated Aug 19, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -36426.9%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -364.269Industry median: -0.34Industry P5: -43.55Peers compared: 261
P/E ratio is 243.88×, higher than 95% of its Biotechnology peers (median 32.39×)Significant
P/E ratio: 243.879Industry median: 32.39Industry P95: 210.5Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $243.79M, lower than 95% of all stocks globallySignificant
Market cap (USD): 243,788,384.507Global P5: 269,387,740.27
Revenue is $18.96M, lower than 95% of all stocks globallySignificant
Revenue (USD): 18,962,536.351Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai MicroPort Endovascular MedTech Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
JCU Corp
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Flytech Technology Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity